InvestorsHub Logo
Followers 23
Posts 1907
Boards Moderated 0
Alias Born 12/14/2009

Re: None

Wednesday, 08/21/2013 11:15:17 AM

Wednesday, August 21, 2013 11:15:17 AM

Post# of 97239
Navidea Awarded NIH SBIR Grant


DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the award of a Small Business Innovation Research (SBIR) grant from the National Institute On Aging (NIA) of the National Institutes of Health (NIH) in connection with the Company's Phase 3 clinical program for its NAV4694 beta-amyloid imaging agent as an aid in the differential diagnosis of Alzheimers disease. The SBIR grant has the potential to provide up to $1.8 million in support, if fully funded, through the conclusion of the Phase 3 clinical study. Funding for the approved first stage of the grant ($259,000) is intended to provide support for initiation activities of the Phase 3 clinical program. Funding of the second stage of the grant is contingent upon meeting specific aims related to the first stage of the grant such as institutional review board approval of the Phase 3 protocol, clinical site contracting and investigator training. Navidea announced the initiation of the Phase 3 program in June 2013


http://seekingalpha.com/news-article/7396392-navidea-awarded-nih-sbir-grant-for-nav4694-beta-amyloid-imaging-agent-phase-3-clinical-program-aimed-at-alzheimer-s-disease

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.